全文获取类型
收费全文 | 17206篇 |
免费 | 1637篇 |
国内免费 | 339篇 |
专业分类
耳鼻咽喉 | 102篇 |
儿科学 | 671篇 |
妇产科学 | 57篇 |
基础医学 | 2707篇 |
口腔科学 | 128篇 |
临床医学 | 1240篇 |
内科学 | 4000篇 |
皮肤病学 | 942篇 |
神经病学 | 293篇 |
特种医学 | 434篇 |
外国民族医学 | 16篇 |
外科学 | 627篇 |
综合类 | 1377篇 |
现状与发展 | 4篇 |
预防医学 | 213篇 |
眼科学 | 254篇 |
药学 | 649篇 |
2篇 | |
中国医学 | 85篇 |
肿瘤学 | 5381篇 |
出版年
2024年 | 14篇 |
2023年 | 307篇 |
2022年 | 295篇 |
2021年 | 648篇 |
2020年 | 729篇 |
2019年 | 660篇 |
2018年 | 647篇 |
2017年 | 679篇 |
2016年 | 607篇 |
2015年 | 785篇 |
2014年 | 1052篇 |
2013年 | 1130篇 |
2012年 | 849篇 |
2011年 | 842篇 |
2010年 | 677篇 |
2009年 | 710篇 |
2008年 | 843篇 |
2007年 | 805篇 |
2006年 | 784篇 |
2005年 | 725篇 |
2004年 | 553篇 |
2003年 | 549篇 |
2002年 | 484篇 |
2001年 | 446篇 |
2000年 | 375篇 |
1999年 | 322篇 |
1998年 | 290篇 |
1997年 | 275篇 |
1996年 | 224篇 |
1995年 | 243篇 |
1994年 | 224篇 |
1993年 | 154篇 |
1992年 | 182篇 |
1991年 | 181篇 |
1990年 | 137篇 |
1989年 | 119篇 |
1988年 | 96篇 |
1987年 | 69篇 |
1986年 | 68篇 |
1985年 | 106篇 |
1984年 | 62篇 |
1983年 | 28篇 |
1982年 | 50篇 |
1981年 | 40篇 |
1980年 | 32篇 |
1979年 | 34篇 |
1978年 | 22篇 |
1977年 | 9篇 |
1976年 | 9篇 |
1966年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 187 毫秒
21.
Shiyu Jiang Yan Qin Hongxin Jiang Biao Liu Jianming Shi Fanlu Meng Peng Liu Jianliang Yang Sheng Yang Xiaohui He Shengyu Zhou Lin Gui Hao Liu Jing Lin Han Han-Zhang Yuankai Shi 《International journal of cancer. Journal international du cancer》2020,147(9):2611-2620
Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a panel consisting of 112 lymphoma-related genes. Subsequently, 81 treatment-naïve patients with measurable disease and followed for over 1 year were included for survival analysis. Collectively, the most commonly seen mutations included IGH fusion (69%), PIM1(33%), MYD88 (29%), BCL2 (29%), TP53 (29%), CD79B (25%) and KMT2D (24%). Patients with TP53 mutations were more likely to have primary refractory disease (87.0% vs 50.0%, P = .009). For those with TP53 disruptive mutations, 91.7% patients were in the primary refractory group. Interestingly, BCL-2 somatic hypermutation was only seen in patients without primary refractory disease (P = .014). In multivariate analysis, BCL-2 amplification (hazard ratio [HR] = 2.94, P = .022), B2M mutation (HR = 2.99, P = .017) and TP53 mutation (HR = 3.19, P < .001) were independently associated with shorter time to progression (TTP). Furthermore, TP53 mutations was correlated with worse overall survival (P = .049). Next, we investigated mutation landscape in patients with wild-type (WT) TP53 (n = 58) and found that patients harboring MYD88 L265P had significantly inferior TTP than those with WT or non-265P (P = .046). Our study reveals the mutation spectrum of treatment-naive Chinese DLBCL patients. It also confirms the clinical significance of TP53 mutations and indicates the prognostic value of MYD88 L265P in TP53 WT patients. 相似文献
22.
23.
24.
25.
目的:研究非霍奇金淋巴瘤(non-Hodgkin' s lymphoma,NHL)骨髓侵犯患者骨髓病灶中间隙连接蛋白(connexin,Cx)43表达情况。 方法:选取我院确诊的非霍奇金淋巴瘤骨髓侵犯患者26例,骨髓组织中查见呈灶性分布且已通过免疫组化证实为反应性淋巴细胞增生的患者9例,正常骨髓组织10例行免疫组化染色,根据阳性率及阳性程度评分后进行统计学分析。 结果:Cx43在NHL样本中的阳性率(30.8%)低于在反应性淋巴细胞增生样本(88.9%)及正常样本(100%)中的阳性率,差异有统计学意义(P<0.05)。而反应性淋巴细胞增生样本和正常样本间Cx43阳性率无统计学意义(P>0.05),但反应性淋巴细胞增生样本的阳性积分明显低于正常样本(P<0.05)。结论:非霍奇金淋巴瘤骨髓侵犯时病灶处Cx43表达情况显著低于反应性淋巴细胞增生及正常骨髓组织。 相似文献
26.
Anna Dietz Nahide Dalda Svenja Zielke Jessica Dittmann Sjoerd J.L. van Wijk Meike Vogler Simone Fulda 《International journal of cancer. Journal international du cancer》2020,147(5):1485-1498
Copy number gains and increased expression levels of cellular Inhibitor of Apoptosis protein (cIAP)1 and cIAP2 have been identified in primary diffuse large B-cell lymphoma (DLBCL) tissues. Second mitochondria-derived activator of caspases (Smac) mimetics were designed to antagonize IAP proteins. However, since their effect as single agents is limited, combination treatment represents a strategy for their clinical development. Therefore, we investigated the Smac mimetic BV6 in combination with proteasome inhibitors and analyzed the molecular mechanisms of action. We discovered that BV6 treatment sensitizes DLBCL cells to proteasome inhibition. We show a synergistic decrease in cell viability and induction of apoptosis by BV6/Carfilzomib (CFZ) treatment, which was confirmed by calculation of combination index (CI) and Bliss score. BV6 and CFZ acted together to trigger activation of BAX and BAK, which facilitated cell death, as knockdown of BAX and BAK significantly reduced BV6/CFZ-mediated cell death. Activation of BAX and BAK was accompanied by loss of mitochondrial membrane potential (MMP) and activation of caspases. Pretreatment with the caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) rescued BV6/CFZ-induced cell death, confirming caspase dependency. Treatment with CFZ alone or in combination with BV6 caused accumulation of NOXA, which was required for cell death, as gene silencing by siRNA or Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated NOXA inactivation inhibited BV6/CFZ-induced cell death. Together, these experiments indicate that BV6 and CFZ cooperatively induce apoptotic cell death via the mitochondrial pathway. These findings emphasize the role of Smac mimetics for sensitizing DLBCL cells to proteasome inhibition with important implications for further (pre)clinical studies. 相似文献
27.
Eriko Yanagida Hiroaki Miyoshi Mai Takeuchi Noriaki Yoshida Kazutaka Nakashima Kyohei Yamada Takeshi Umeno Yasumasa Shimasaki Takuya Furuta Masao Seto Koichi Ohshima 《Hematological oncology》2020,38(5):680-688
The interaction of CD47 and signal-regulatory protein alpha (SIRPα) induces “don't eat me signal”, leading suppression of phagocytosis. This signal can affect the clinical course of malignant disease. Although CD47 and SIRPα expression are associated with clinicopathological features in several neoplasms, the investigation for adult T-cell leukemia/lymphoma (ATLL) has not been well-documented. This study aimed to declare the association between CD47 and SIRPα expression and clinicopathological features in ATLL. We performed immunostaining on 73 biopsy samples and found that CD47 is primarily expressed in tumor cells, while SIRPα is expressed in non-neoplastic stromal cells. CD47 positive cases showed significantly higher FoxP3 (P = .0232) and lower CCR4 (P = .0214). SIRPα positive cases presented significantly better overall survival than SIRPα negative cases (P = .0132). SIRPα positive cases showed significantly HLA class I (P = .0062), HLA class II (P = .0133), microenvironment PD-L1 (miPD-L1) (P = .0032), and FoxP3 (P = .0229) positivity. In univariate analysis, SIRPα expression was significantly related to prognosis (Hazard ratio [HR] 0.470; 95% confidence interval [CI] 0.253-0.870; P = .0167], although multivariate analysis did not show SIPRα as an independent prognostic factor. The expression of SIRPα on stromal cells reflects activated immune surveillance mechanism in tumor microenvironment and induce good prognosis in ATLL. More detailed studies for gene expression or genomic abnormalities will disclose clinical and biological significance of the CD47 and SIRPα in ATLL. 相似文献
28.
29.
30.